Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
5.16
-0.07 (-1.34%)
At close: Oct 23, 2025, 4:00 PM EDT
5.16
0.00 (0.00%)
After-hours: Oct 23, 2025, 7:02 PM EDT
Tvardi Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Tvardi Therapeutics stock have a consensus rating of "Buy" and an average price target of $51.67, which forecasts a 901.36% increase in the stock price over the next year. The lowest target is $15 and the highest is $78.
Price Target: $51.67 (+901.36%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tvardi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 2 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 5 | 5 | 5 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 14, 2025 |
| BTIG | BTIG | Strong Buy Maintains $55 → $15 | Strong Buy | Maintains | $55 → $15 | +190.70% | Oct 13, 2025 |
| Barclays | Barclays | Buy Initiates $61 | Buy | Initiates | $61 | +1,082.17% | Oct 13, 2025 |
| Raymond James | Raymond James | Buy Initiates $62 | Buy | Initiates | $62 | +1,101.55% | Jul 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $52 | Buy | Initiates | $52 | +907.75% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
530.40K
Revenue Next Year
n/a
from 530.40K
EPS This Year
-2.82
from -4.59
EPS Next Year
-3.91
from -2.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.7M | n/a | |
| Avg | 530,400 | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.46 | -1.49 | |
| Avg | -2.82 | -3.91 | |
| Low | -3.36 | -5.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.